1. Home
  2.  » 
  3. Cell Therapy
  4.  » 
  5. iPSCs
  6.  » Characterization of Our iPSCs

Characterization of Our iPSCs

Back to top

ESC Comparability

A comparison of the transcriptomic profiles of our iPSCs, their source cord blood cells, and human ESCs. Morphologically, our iPSCs benchmark comparably to hESCs

Karyotype and mutation load measured by whole genome sequencing demonstrate that our iPSCs maintain the genetic integrity of their source cord blood cells
Karyotype and mutation load measured by whole genome sequencing demonstrate that our iPSCs maintain the genetic integrity of their source cord blood cells

A comparison of the transcriptomic profiles of our iPSCs, their source cord blood cells, and human ESCs. Morphologically, our iPSCs benchmark comparably to hESCs

Back to top

Differentiation and Immunogenicity

Our cell lines have demonstrated differentiation potential into various cell types including neurons, cardiomyocytes, retinal pigment epithelial cells and more.

HLA (human leukocyte antigen) genes are major determinants of tissue recognition and rejection in the body. The thousands of HLA variants in the population complicate cell donor-recipient matching and often lead to immune rejection. By contrast, HLA-homozygous (HLAh) donors mitigate the immunogenicity challenges. Carrying a single HLA haplotype, HLAh cell lines genetically match a statistically larger portion of the population from their starting material.

Karyotype and mutation load measured by whole genome sequencing demonstrate that our iPSCs maintain the genetic integrity of their source cord blood cells

HLA-homozygous iPSCs –significantly reduces immunogenicity with high expansion capacity and broad differentiation potential across various cell types

Back to top

Regulatory Standardized

Our cell lines have demonstrated differentiation potential into various cell types including neurons, cardiomyocytes, retinal pigment epithelial cells and more.

HLA (human leukocyte antigen) genes are major determinants of tissue recognition and rejection in the body. The thousands of HLA variants in the population complicate cell donor-recipient matching and often lead to immune rejection. By contrast, HLA-homozygous (HLAh) donors mitigate the immunogenicity challenges. Carrying a single HLA haplotype, HLAh cell lines genetically match a statistically larger portion of the population from their starting material.